Last edition
News about "Oncology drug development"
The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research have partnered to launch KLEOS, a pioneering adaptive clinical trial platform designed to accelerate the development of new therapies for colorectal cancer and improve patient outcomes.
Oncology Drug Development | 01/06/2026 | By News Bureau
Tempus Launches Next-Generation Lens AI Platform for Oncology Drug Development
Tempus has unveiled the next-generation Lens platform, expanding its agentic AI capabilities for oncology drug development by leveraging over a decade of longitudinal real-world data and advanced analytics to generate actionable insights for biopharma research, clinical development, and precision medicine.
Oncology Drug Development | 01/06/2026 | By News Bureau | 155
Antengene Corporation receives CDE endorsement to begin pivotal phase 3 CLINCH-3 study of ATG-022
Antengene has received approval from China’s Center for Drug Evaluation to initiate the pivotal Phase 3 CLINCH-3 study of ATG-022, advancing the development of its innovative antibody-drug conjugate for CLDN18.2-positive gastric cancers.
Oncology Drug Development | 30/05/2026 | By News Bureau
Solu Therapeutics Receives FDA Fast Track Status for STX-0712 in CMML Treatment
Solu Therapeutics receives US Food and Drug Administration (FDA) Fast Track designation for STX-0712 to treat chronic myelomonocytic leukemia (CMML), supporting accelerated development for patients with relapsed or treatment-resistant disease and limited therapeutic options.
Oncology Drug Development | 28/05/2026 | By News Bureau
Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer
Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.
Oncology Drug Development | 22/05/2026 | By News Bureau
Merck's Phase 3 TroFuse-005 Trial Shows Survival Benefit of Sac-TMT in Advanced Endometrial Cancer
Merck announced that its phase 3 TroFuse-005 trial evaluating investigational antibody-drug conjugate Sacituzumab Tirumotecan (sac-TMT) met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
Oncology Drug Development | 19/05/2026 | By News Bureau | 104
Scientists at The University of Tulsa have developed new memantine-based compounds capable of crossing the blood-brain barrier and demonstrating higher anticancer activity against glioblastoma cells than standard chemotherapy treatments.
Oncology Drug Development | 12/05/2026 | By News Bureau
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
Oncology Drug Development | 07/05/2026 | By News Bureau | 101
U.S. Food and Drug Administration grants Priority Review and Breakthrough Therapy status to combination therapy showing significant survival benefits in advanced HER2-positive gastric and esophageal cancers.
Oncology Drug Development | 01/05/2026 | By News Bureau
U.S. Food and Drug Administration grants Priority Review and Breakthrough Therapy status to combination therapy showing significant survival benefits in advanced HER2-positive gastric and esophageal cancers.
Oncology Drug Development | 01/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy